Tempus AI

Latest news

1. 23 Oct
   Pathos AI partners with Bristol Myers, Tempus AI and raises $237M for drug-development tools

   Pathos AI announced a collaboration with Bristol Myers Squibb and Tempus AI to develop AI tools for Alzheimer's and other neurological disorders, and raised $237 million in a Series E round led by Bristol Myers. The deal includes a five-year, $55 million data license from Tempus and strategic access and limited exclusive rights for Bristol Myers to use Pathos's Foundry platform.

   Deals · 1 source

   

Articles

No articles about Tempus AI yet.